NHS ENGLAND SPECIALISED SERVICES
CLINICAL PANEL REPORT

Date: 17 April 2019
Intervention: Extracorporeal membrane oxygenation (ECMO)
Indication: Bridge to lung transplant
ID: 1803
Gateway: Policy Gateway 2 (Round 3)
Programme: Internal Medicine (IM)
CRG: Specialised Respiratory

Information provided to the panel

Policy proposition
Evidence review produced by Public Health England in September 2018
CPAG Summary Report
Clinical Panel report (October 2018) (Round 1)
Clinical Panel report (December 2018) (Round 2)
Response from NHS Blood & Transplant following Round 1
Notes from the ECMO Extraordinary meeting held January 2019
Additional report for Clinical Panel

Key elements discussed

The panel has discussed the bridge to transplant issue before. The intervention is reasonable for the individual patient. The panel’s concern remain whether prioritising patients acutely ill for a lung transplant deprives others who may have an equal place in access to lung transplant.

The panel wanted to hear how the prioritisation of patients was undertaken by NHS Blood & Transplant (NHS-BT) to identify whether the priority given to the acutely ill is consistent. A working group was established between NHS England and NHS-BT to explore the issues.

Patients included are only those who were already on the transplant waiting list and then acutely deteriorated. In this situation these patients are added to a ‘super-urgent waiting list for a lung’. The patients tend to be younger with cystic fibrosis. So the argument was that the younger patients would have a longer period of benefit.

The evidence from NHS-BT is that there is a different case mix in this patient group. As the super-urgent list is recent (2 years) there is not an evidence base that they have better outcome than the wider cohort waiting transplant.

The population health approach is that the number of organs available is limited. Those with rapid deterioration will take an organ that may have been available to someone else on the transplant waiting list. The early outcome of transplant tends to be worse from those receiving
an organ from ECMO. The length of stay following transplant was significantly worse for those on ECMO compared to the comparator group (mechanical ventilation).

Clinicians identify the younger patients as ‘more deserving’ to lung transplant. The policy redistributes organs to the younger patients at a greater cost to the NHS (ITU ECMO support), and at slightly worse acute outcomes and uncertain longer term improved outcome.

If there is a need to prioritise the younger patients then the Panel were concerned that these patients had not been already identified as a higher priority on the transplant waiting list.

It was raised whether there was a further inequity that there are other patients who suddenly deteriorate who were not already on the transplant waiting list. It was identified that, probably, it is too complex to add a suddenly deteriorating patient to the transplant waiting list.

The access to the super-urgent waiting list for liver transplant was discussed.

There was a vote taken of panel members (yes 5, no 4) to decide on the proposal next steps. Members were divided in their view.

**Recommendation**

The policy should progress to stakeholder testing and consultation as a ‘routine commissioning’ position. At both steps the proposal should be accompanied by the key questions of individual access vs population equity.

**Why the panel made these recommendations**

Clinical commissioners have to consider whether the rule of rescue is being applied (see example paper on the subject [http://discovery.ucl.ac.uk/1358337/1/Orr_Wolff_Reconciling.pdf](http://discovery.ucl.ac.uk/1358337/1/Orr_Wolff_Reconciling.pdf)). There is a dilemma between the decision where to place an investment for additional healthcare expenditure for the benefit of the population against the moral dilemma of managing the care of an individual where an intervention may prevent death. The mortality on the lung transplant waiting list is high (more than 20%), ECMO is a high cost treatment. It is clear that introducing this policy will not increase the numbers of organs available to transplant. The Clinical Panel (by design) mixes experts in population health with individuals working in clinical care, the decision to proceed was marginal. It recommends that a full debate is held by CPAG considering the conflicting stances of such a policy.

**Documentation amendments required**

There should be a document produced to accompany the policy to CPAG which outlines the benefit to the population versus the benefit to the individual.

Declarations of Interest of Panel Members: A member declared a personal conflict and did not take part in the Panel discussion.

Panel Chair: James Palmer, Medical Director

**Post meeting note:**

The IM PoC agreed key questions that needed to be asked at stakeholder and public consultation of individual access versus population equity.

An additional report was included in the documents at both the stakeholder and public consultation to provide additional information for consultees on the lung allocation scheme, the patients in the super-urgent group and their outcomes.